Loading...
Market
Will AstraZeneca face another patent lawsuit from Pfizer by the end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Public court records and news reports
Story
AstraZeneca Overturns $107.5 Million Verdict in Patent Dispute with Pfizer
Aug 14, 2024, 07:00 PM
AstraZeneca has successfully overturned a jury verdict that required the company to pay $107.5 million for infringing cancer-drug patents owned by Wyeth, a subsidiary of Pfizer. The decision was made by a federal judge in Delaware, marking a significant legal victory for AstraZeneca. Pfizer, which acquired Wyeth in 2009, initially filed the lawsuit against AstraZeneca in 2021. This outcome is seen as a milestone decision for UK companies, particularly for AstraZeneca's CEO Pascal Soriot and the shareholders who supported his vision.
View original story
Similar markets
Yes • 50%
No • 50%
Patent infringement lawsuit • 25%
Settlement agreement • 25%
Licensing agreement • 25%
No major legal action • 25%
Pfizer wins the appeal • 25%
AstraZeneca wins the appeal • 25%
Settlement reached before appeal decision • 25%
Appeal dismissed • 25%
Yes • 50%
No • 50%
Counter-sue • 33%
Motion to dismiss • 33%
Settlement offer • 33%
Stock price increases by more than 10% • 25%
Stock price increases by 5-10% • 25%
Stock price remains within +/- 5% • 25%
Stock price decreases by more than 5% • 25%
Upheld • 25%
Overturned • 25%
Settled • 25%
Other • 25%